Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of …

Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of … | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado

The only conference focused solely on the pharmaceutical development of peptide therapeutics.

Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of …

Peptide News from Biotech and Pharma, Raw News September 25, 2017

Reltecimod (AB103) is a rationally designed peptide that binds to the CD28 co-stimulatory receptor to modulate the host's immune response to severe ...